The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRtw Biotech Regulatory News (RTW)

Share Price Information for Rtw Biotech (RTW)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.43
Bid: 1.43
Ask: 1.45
Change: 0.00 (0.00%)
Spread: 0.02 (1.399%)
Open: 1.42
High: 1.43
Low: 1.42
Prev. Close: 1.43
RTW Live PriceLast checked at -
RTW Venture is an Investment Trust

To achieve positive absolute performance and superior long-term capital appreciation, with a focus on forming, building, and supporting world-class life sciences, biopharmaceutical and medical technology companies.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Notice of AGM

2 Jun 2021 07:00

RNS Number : 4897A
RTW Venture Fund Limited
02 June 2021
 

LEI: 549300Q7EXQQH6KF7Z84

2 June 2021

RTW Venture Fund Limited

Notice of Annual General Meeting

RTW Venture Fund Limited (the "Company") announces that its Annual General Meeting ("AGM") will be held at 1st Floor Royal Chambers, St Julian's Avenue St Peter Port, Guernsey on 22 June 2021 at 14.00 BST. The Notice of AGM will shortly be dispatched to all shareholders.

A copy of the Notice of AGM has been submitted to the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism The Notice of AGM may also be viewed on the Company's website at https://www.rtwfunds.com/venture-fund/.

The Annual Report and Audited Financial Statements for the year ended 31 December 2020 (the "Annual Report") is also available on the Company's website https://www.rtwfunds.com/venture-fund/ at  and on the National Storage Mechanism at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

The Board anticipates that at the time of the Annual General Meeting Shareholders will be able to attend the meeting in person, subject to any COVID-19 restrictions that might be imposed by the States of Guernsey. However, the Board recommends that, due to continuing uncertainty, Shareholders appoint the Chairman as proxy and provide voting instructions in advance of the AGM. Should it be required, arrangements will be made by the Company to ensure that the minimum number of Shareholders required to form a quorum will attend the AGM so that it may proceed. You will not have received a hard copy proxy form for the 2021 Annual General Meeting ("AGM") in the post. You can instead submit your proxy vote electronically by accessing the shareholder portal at www.signalshares.com, logging in and selecting the 'Vote Online Now' link. Full details of how to vote are set out in notes 2 and 3 in the Notes to the Notice of Meeting. Please submit your proxy vote so as to reach the Company's registrar as soon as possible and in any event no later than 2pm on Friday 18 June 2021 or, if you are a CREST member, by using the service provided by Euroclear. The completion of the form of proxy will not preclude a member from attending and voting in person at the meeting if it is so allowed.

The situation is developing rapidly and shareholders should note that further changes may need to be put in place at short notice in relation to the AGM this year. Updates on the status of the AGM and any changes to the proceedings of the meeting will be published on https://www.rtwfunds.com/venture-fund/ and announced to the market. If any shareholder has questions related to the business of the AGM, please submit your queries at https://www.rtwfunds.com/venture-fund/ by 14.00 BST on 18 June 2021. We will endeavour to answer every shareholder question and responses will be posted on the Company's website after the AGM.

For Further Information

RTW Investments, LP +1 (646) 597 6980Stephanie Sirota, Chief Business Officer

Alexandra Taracanova, PhD, Director of Investor Relations

Julia Enright, Senior Business Development Associate

 

Elysium Fund Management Limited +44 (0) 14 8181 0100

Joanna Duquemin Nicolle, Chief Executive Officer

Sadie Morrison, Managing Director

 

J.P. Morgan Cazenove +44 (0)20 7742 4000

William Simmonds

Jérémie Birnbaum

James Bouverat (Sales)

 

Barclays +44 (0)20 7623 2323

Tom Swerling

Andrew Tusa

 

 

About RTW Venture Fund Limited:

RTW Venture Fund Limited (LSE: RTW) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Venture Fund invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives.

RTW Venture Fund Limited is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

Visit the RTW website at www.rtwfunds.com for more information.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NOASSFFMFEFSEFM
Date   Source Headline
9th Feb 20247:00 amRNSRTW Biotech Opp. – Investment Update: Kyverna IPO
1st Feb 20247:00 amRNSTotal Voting Rights
31st Jan 20247:00 amRNSTransaction in Own Shares
30th Jan 20247:00 amRNSUpdate on Arix Transaction
24th Jan 20247:00 amRNSTransaction in Own Shares
22nd Jan 20247:00 amRNSAcacia stake purchase & capital allocation plan
18th Jan 20247:00 amRNSTransaction in Own Shares
15th Jan 20247:00 amRNSMonthly Valuation Update, December Factsheet
10th Jan 20247:00 amRNSTransaction in Own Shares
8th Jan 20249:00 amRNSInvestment Update
5th Jan 20241:00 pmRNSPublication of a Prospectus
2nd Jan 20247:00 amRNSTotal Voting Rights
14th Dec 20237:00 amRNSMonthly Valuation Update, November Factsheet
6th Dec 20237:00 amRNSTransaction in Own Shares
1st Dec 20237:01 amRNSTotal Voting Rights
1st Dec 20237:00 amRNSTransaction in Own Shares
13th Nov 20237:00 amRNSPortfolio Company Update: CARGO Therapeutics, Inc
13th Nov 20237:00 amRNSTransaction in Own Shares
13th Nov 20237:00 amRNSMonthly Valuation Update, October Factsheet
9th Nov 20237:00 amRNSTransaction in Own Shares
8th Nov 20237:00 amRNSTransaction in Own Shares
1st Nov 202310:51 amEQSEdison issues flash on RTW Biotech Opportunities (RTWBIO): Significant acquisition of Arix Bioscience’s assets
1st Nov 20237:06 amRNSRTW Biotech to acquire Arix Bioscience's assets
1st Nov 20237:05 amRNSTotal Voting Rights
16th Oct 20237:00 amRNSTransaction in Own Shares
13th Oct 20237:00 amRNSMonthly Valuation Update, Sep Factsheet, Q3 Letter
3rd Oct 20234:00 pmRNSDirector Declaration
2nd Oct 20237:00 amRNSTotal Voting Rights
18th Sep 20237:00 amRNSTransaction in Own Shares
15th Sep 20237:00 amRNSMonthly Valuation Update & August Factsheet
14th Sep 20237:00 amRNSUpdate on Largest Core Portfolio Position
13th Sep 20237:00 amRNSHalf-year Report
6th Sep 20237:00 amRNSTransaction in Own Shares
4th Sep 202311:00 amRNSAdditional Investment in Portfolio Company
14th Aug 20237:00 amRNSMonthly Valuation Update & July Factsheet
4th Aug 20237:30 amRNSEdison issues update on RTW Venture Fund (RTW)
1st Aug 202312:30 pmRNSTotal Voting Rights
21st Jul 20237:00 amRNSTransaction in Own Shares
17th Jul 20237:00 amRNSPortfolio Company Update: Apogee Therapeutics IPO
17th Jul 20237:00 amRNSMonthly Valuation Update, Factsheet & Q2 Letter
5th Jul 20237:00 amRNSCapital Allocation Plans from Prometheus Sale
30th Jun 202310:00 amRNSPortfolio Company Update: Tourmaline Bio
27th Jun 20237:00 amRNSChange of Name
21st Jun 20234:22 pmRNSResult of AGM
14th Jun 20237:00 amRNSMonthly Valuation Update & Factsheet
1st Jun 20237:00 amRNSNotice of AGM
12th May 20237:00 amRNSMonthly Valuation Update & Factsheet
9th May 20237:00 amRNSPortfolio Company Update: Acelyrin IPO
2nd May 20237:00 amRNSAnnual Financial Report
26th Apr 20237:00 amRNSNew Investment in Abdera Therapeutics

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.